Lidocaine weighs 234.34. Procaine weighs 236.31. Both carry an aromatic ring at one end, a tertiary diethylamino group at the other, and a two-atom bridge between them. On paper they are near-twins. Telling them apart in a sample is done by retention time and spectrum against a procaine hydrochloride analytical reference standard run alongside the lidocaine one.
The bridge is where they diverge. Procaine is 2-(diethylamino)ethyl 4-aminobenzoate — an ester. Lidocaine is 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide — an amide. That single substitution of nitrogen for oxygen moved the drug’s metabolism from the bloodstream to the liver and created an entirely new class of local anaesthetic.
Why the lidocaine amide bond survives what an ester does not
The difference is electronic. In an amide, the nitrogen lone pair delocalises into the carbonyl, giving the C–N bond partial double-bond character. A 2018 review in Molecules describes exactly this: the resonance produces a planar geometry and hinders free rotation around the CO–N bond. An ester oxygen donates its lone pair far less effectively, so the ester carbonyl carbon stays more electrophilic and more open to attack by water.
The consequence is a stability gap measured in orders of magnitude. The same review puts the half-life of an amide bond at pH 7 at 267 years, with hydrolysis dominated by direct water attack across the pH 5–9 range, and notes that enzymes accelerate the reaction by at least 109–1010-fold. The benchmark measurements behind figures of this kind were made by Radzicka and Wolfenden, reported in the Journal of the American Chemical Society in 1996.
An anaesthetic molecule injected into tissue therefore faces two very different fates depending on one atom.
Two linkers, two organs
Cherobin and Tavares, writing in Anais Brasileiros de Dermatologia in 2020, put the classification plainly: the intermediate chain can be ester or amide, and that chain is what determines the class.
Ester anaesthetics are degraded by plasma pseudocholinesterase, with water-soluble metabolites cleared in urine. Hydrolysis begins the moment the drug meets plasma. Amide anaesthetics are metabolised in the liver instead. For lidocaine specifically, Karnina and colleagues describe hepatic dealkylation to monoethylglycinexylidide (MEGX), an active metabolite they report as about 80 % as potent as the parent compound, which is then converted by CYP3A4 to N-ethylglycine and glycinexylidide.
| Procaine (ester) | Lidocaine (amide) | |
|---|---|---|
| PubChem CID | 4914 | 3676 |
| Formula | C13H20N2O2 | C14H22N2O |
| Molecular weight | 236.31 | 234.34 |
| XLogP3 | 1.9 | 2.3 |
| Linker | –COO– | –CONH– |
| Primary metabolism | plasma pseudocholinesterase | hepatic dealkylation, CYP3A4 |
One structural detail deserves separate attention. Lidocaine’s aromatic ring is 2,6-dimethylphenyl — two methyl groups flanking the nitrogen attachment point. Those ortho substituents sit directly over the amide bond and shield the carbonyl sterically, on top of the electronic protection resonance already provides. The xylidide motif is not decorative; it is part of why the molecule is hydrolytically robust enough to be autoclaved, stored in solution and used as a stable formulation.
1943: from a plant alkaloid to LL30
Lidocaine did not begin as an anaesthetic programme. Nils Löfgren arrived at it through systematic modification of gramine, a plant-derived alkaloid, and synthesised the compound that became xylocaine in 1943. His collaborator Bengt Lundqvist tested it on himself, performing conduction and spinal anaesthesia, and the compound carried the working designation LL30 after the two chemists’ initials. Torsten Gordh conducted the clinical trials. On 22 November 1943 the Swedish company Astra acquired worldwide rights to manufacture and distribute it.
What followed is the clearest evidence that the amide linker, not the specific molecule, was the discovery. Mesocaine, prilocaine, mepivacaine, bupivacaine, etidocaine and articaine all followed as amide-linked agents. An entire structural class descends from that one bond.
Karnina and colleagues also note a practical divergence that emerged from the switch: unlike procaine, lidocaine at therapeutic concentrations avoids the blood-pressure reduction and diminished myocardial contractility associated with the older compound.
The allergy story, and why it is not settled
The standard explanation for the class split runs as follows. Hydrolysis of an ester-linked anaesthetic liberates para-aminobenzoic acid (PABA); PABA and its derivatives are allergenic; amides produce no PABA and are therefore safer. Cherobin and Tavares repeat this account, identifying PABA as the ester metabolite responsible for the risk of allergic reactions, while also noting that true IgE-mediated allergy to local anaesthetics of any class is estimated at under 1 %.
That explanation has been directly challenged. Weinschenk and co-workers published a double-blind, placebo-controlled study in BioMed Research International in 2017 covering 177 patients and 340 intracutaneous injections of procaine, lidocaine, mepivacaine and saline placebo. They observed no type-1 allergy in any group. Procaine and mepivacaine produced larger wheals than lidocaine or saline, but the reactions followed a crescendo–decrescendo course resolving within 15 minutes, a pattern the authors read as vasodilatation rather than allergy.
Their historiographic point is the sharper one. The authors trace the forty-year belief that esters are more allergenic than amides largely to a single 1970 study, propagated through textbooks, and report finding no clinical data supporting the PABA cross-allergy mechanism.
This is worth stating precisely. The chemistry of the ester-versus-amide split — different hydrolytic stability, different metabolising organ, different metabolites — is solid and directly measurable. The allergological interpretation layered on top of it is contested, and a reader should treat the two claims as having very different evidential weight.
What the bond means in the laboratory
For analytical work the ester/amide distinction shows up long before any biology. Ester anaesthetics hydrolyse in aqueous solution and in the presence of esterase activity, so sample handling, storage temperature and matrix choice all change what the instrument sees. Amide anaesthetics are comparatively forgiving and give cleaner long-term stability data.
Lidocaine’s own analysis is complicated instead by its metabolites: quantifying the parent compound without resolving MEGX and glycinexylidide will overstate it. Method development for these separations is normally anchored to an analytical reference standard of certified identity and purity, because retention-time matching against an uncharacterised material proves nothing about what is actually in the vial.
Frequently asked questions
What is the difference between ester and amide local anaesthetics?
The difference is the intermediate chain linking the aromatic ring to the amine. Esters such as procaine carry a –COO– bridge and are degraded by plasma pseudocholinesterase, yielding water-soluble metabolites excreted in urine. Amides such as lidocaine carry a –CONH– bridge and are metabolised in the liver. The amide bond is far more resistant to spontaneous hydrolysis.
Why is an amide bond more stable than an ester bond?
Nitrogen donates its lone pair into the carbonyl far more effectively than ester oxygen does, giving the amide C–N bond partial double-bond character, a planar geometry and a hindered rotation barrier. This delocalisation lowers the electrophilicity of the carbonyl carbon and raises the barrier to nucleophilic attack by water. One review places the amide half-life at pH 7 at 267 years.
Who discovered lidocaine and when?
Nils Löfgren synthesised the compound in 1943 in Sweden, arriving at it through successive modifications of the plant alkaloid gramine. Bengt Lundqvist evaluated it in self-experiments and Torsten Gordh ran the clinical trials. It was designated LL30 after the two chemists, and Astra acquired worldwide manufacturing and distribution rights on 22 November 1943.
Are ester local anaesthetics really more allergenic than amides?
The claim is standard in textbooks, attributed to para-aminobenzoic acid released when esters hydrolyse. It has been challenged. A 2017 double-blind, placebo-controlled study of 177 patients and 340 intracutaneous injections found no type-1 allergy to procaine, lidocaine or mepivacaine, and traced the belief largely to a single 1970 study. True IgE-mediated allergy to local anaesthetics is estimated at under 1 % overall.
References
- PubChem CID 3676, Lidocaine — computed properties
- PubChem CID 4914, Procaine — computed properties
- Mahesh S, Tang K-C, Raj M. Amide Bond Activation of Biological Molecules. Molecules 2018;23(10):2615
- Radzicka A, Wolfenden R. Rates of Uncatalyzed Peptide Bond Hydrolysis in Neutral Solution and the Transition State Affinities of Proteases. J Am Chem Soc 1996;118(26):6105–6109
- Cherobin ACFP, Tavares GT. Safety of local anesthetics. An Bras Dermatol. 2020;95(1):82–90
- Karnina R, Arif SK, Hatta M, Bukhari A. Molecular mechanisms of lidocaine. Ann Med Surg (Lond). 2021;69:102733
- Weinschenk S, et al. Local Anesthetics, Procaine, Lidocaine, and Mepivacaine Show Vasodilatation but No Type 1 Allergy: A Double-Blind, Placebo-Controlled Study. Biomed Res Int. 2017;2017:9804693
- Stolyarenko P. History of the first amide local anesthetic (on the 80th anniversary of xylocaine synthesis). 2023
- Gordh T, Gordh TE, Lindqvist K, Warner DS. Lidocaine: The Origin of a Modern Local Anesthetic. Anesthesiology 2010;113(6):1433–1437
Research use only. Nonsensia supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Chemistry & Discovery
This article is part of our guide to Where Research Compounds Come From: Discovery, Synthesis and Structure.
The compound discussed in this article is available as an analytical reference standard: Lidocaine ≥99.48% – Analytical Reference Standard, 1000 mg | CAS 137-58-6.